Opportunity Information: Apply for RFA HL 14 029
Apply for RFA HL 14 029
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233 National Center on Sleep Disorders Research 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jan 7, 2015 and posted on Oct 23, 2013.
- Applicants must submit their applications by Jan 8, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education City or township governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) For profit organizations other than small businesses Special district governments County governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity RFA-HL-14-029 supports exploratory, early-stage basic research projects (R21 mechanism) focused on understanding how HIV leads to diseases of the heart, lung, and blood in both adults and children. The core purpose is to dig into fundamental biological mechanisms that drive HIV-associated heart, lung, and blood (HLB) conditions, including how those mechanisms may differ when people are receiving antiretroviral therapy (ART). The intent is not simply to describe clinical patterns, but to generate the kind of foundational mechanistic evidence that can point to new therapeutic strategies, reveal new molecular targets, and guide smarter intervention design for HIV-related HLB complications.
Projects under this FOA are expected to be strongly rooted in basic science and pathogenesis. The announcement emphasizes mechanistic investigations that can be carried out using a wide range of research platforms, including primary cell types relevant to HLB biology, patient-derived biospecimens, computational or systems biology models, and animal models, especially those already established for HIV research. In practical terms, applicants could propose studies that examine how HIV infection, viral proteins, chronic immune activation, inflammation, coagulation changes, endothelial dysfunction, or immune cell dysregulation contribute to cardiovascular, pulmonary, or hematologic disease processes. The FOA also explicitly highlights the importance of studying these pathways both in the absence of ART and in the setting of ART, recognizing that treated HIV infection can still be associated with persistent immune and inflammatory disturbances and long-term organ system complications.
This is a discretionary grant program administered by the National Institutes of Health, aligned with several health research areas reflected in its CFDA listings, including cardiovascular diseases research (93.837), lung diseases research (93.838), blood diseases and resources research (93.839), and sleep disorders research (93.233). The mechanism is an R21, which typically signals support for innovative, exploratory projects that may be high-impact but still at a stage where major preliminary data may be limited. The award ceiling listed for this opportunity is $200,000, and there is no cost sharing or matching requirement, which means applicants are not required to contribute non-federal funds as a condition of the award.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), small businesses, for-profit organizations (other than small businesses), and multiple levels of government (state, county, city/township, special district). The FOA also includes a range of mission- and community-focused institutions and organizations as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, and eligible federal agencies. Foreign institutions (non-U.S. entities) are not eligible to apply as applicant organizations; however, non-domestic components of U.S. organizations may participate, and foreign components are allowed consistent with the NIH Grants Policy Statement, meaning international collaborators can be part of the science when justified.
From an administrative standpoint, this FOA was originally posted on October 23, 2013, with key dates showing an original closing date of January 8, 2015, and a current closing date listed as January 8, 2016, with archiving on February 8, 2016. The official NIH announcement and full requirements were made available through the NIH Grants Guide (the provided link points to the full text). For access or technical issues related to the announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, the opportunity is designed for teams aiming to clarify the underlying biology of HIV-associated heart, lung, and blood diseases, including how ART and the treated-HIV state influence disease pathways. The expected payoff is a stronger mechanistic foundation that can accelerate therapeutic discovery and improve strategies to prevent or treat HIV-related HLB complications across the lifespan, from pediatric populations to older adults living long-term with HIV.
Frequently Asked Questions (FAQs)
What is the funding opportunity described here?
This is an NIH funding opportunity announcement: RFA-HL-14-029. It supports exploratory, early-stage basic research projects using the NIH R21 grant mechanism.
What is the main goal of RFA-HL-14-029?
The goal is to understand the fundamental biological mechanisms (pathogenesis) by which HIV leads to diseases of the heart, lung, and blood (HLB) in both adults and children, including how those mechanisms may differ in people receiving antiretroviral therapy (ART).
What kinds of research are most responsive to this FOA?
Projects that are strongly rooted in basic science and mechanistic investigations of HIV-associated heart, lung, and blood conditions. The emphasis is on generating foundational mechanistic evidence that can point to new therapeutic strategies, identify molecular targets, and guide better interventions.
Is this opportunity focused on clinical descriptions of disease patterns?
No. The intent is not simply to describe clinical patterns. The FOA emphasizes mechanistic, basic research aimed at uncovering biological pathways and drivers of HIV-associated HLB disease.
Which organ systems and disease areas are included?
The FOA focuses on HIV-associated diseases and complications affecting the heart (cardiovascular), lung (pulmonary), and blood (hematologic) systems. It is intended to apply across the lifespan, including pediatric and adult populations.
Does the FOA encourage research in both untreated and treated HIV?
Yes. The announcement highlights the importance of studying disease pathways both in the absence of ART and in the setting of ART, recognizing that treated HIV infection can still be associated with persistent immune and inflammatory disturbances and long-term organ system complications.
What biological mechanisms or pathways might applicants investigate under this FOA?
The FOA describes examples such as HIV infection and viral proteins, chronic immune activation, inflammation, coagulation changes, endothelial dysfunction, and immune cell dysregulation as potential contributors to cardiovascular, pulmonary, or hematologic disease processes.
What types of research platforms or models are mentioned as appropriate?
The FOA notes that mechanistic investigations may use a range of platforms, including primary cell types relevant to HLB biology, patient-derived biospecimens, computational or systems biology models, and animal models, especially those already established for HIV research.
What grant mechanism is used, and what does that imply?
The mechanism is an R21, which typically supports innovative, exploratory projects that may be high-impact and early-stage, where major preliminary data may be limited.
What is the award ceiling for this opportunity?
The award ceiling listed is $200,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
Which organizations are eligible to apply?
Eligibility is broad and includes U.S.-based public and private institutions of higher education; nonprofit organizations (with and without 501(c)(3) status); small businesses; for-profit organizations (other than small businesses); and government entities at the state, county, city/township, and special district levels. Eligible federal agencies are also included.
Are minority-serving and community-based organizations eligible?
Yes. The FOA explicitly includes institutions and organizations such as HBCUs, Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, and faith-based or community-based organizations as eligible applicants.
Can foreign institutions apply as the main applicant?
No. Foreign (non-U.S.) institutions are not eligible to apply as applicant organizations.
Can international collaborators or foreign components be involved in the project?
Yes. Non-domestic components of U.S. organizations may participate, and foreign components are allowed consistent with the NIH Grants Policy Statement. This means international collaborators can be part of the science when justified.
Which NIH/CFDA research areas are associated with this opportunity?
The program is aligned with several CFDA listings, including cardiovascular diseases research (93.837), lung diseases research (93.838), blood diseases and resources research (93.839), and sleep disorders research (93.233).
Who administers this grant program?
This is a discretionary grant program administered by the National Institutes of Health (NIH).
What are the key dates mentioned for this FOA?
The FOA was originally posted on October 23, 2013. Key dates include an original closing date of January 8, 2015, a current closing date listed as January 8, 2016, and archiving on February 8, 2016.
Where can applicants find the official announcement and full requirements?
The official NIH announcement and full requirements were made available through the NIH Grants Guide (the referenced link points to the full text).
Who should be contacted for access or technical issues related to the announcement?
For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What kind of impact is NIH looking for from projects funded under this FOA?
The expected payoff is a stronger mechanistic foundation to accelerate therapeutic discovery and improve strategies to prevent or treat HIV-related heart, lung, and blood complications, including in people living long-term with HIV and in pediatric populations.
Browse more opportunities from the same category: Health
Next opportunity: Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)
Previous opportunity: Request for Information (RFI)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 14 029
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 14 029) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 024 Funding Number: RFA HL 14 024 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21) Apply for PAR 13 380 Funding Number: PAR 13 380 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) Apply for PAR 13 379 Funding Number: PAR 13 379 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Marquette, Michigan Omaha, Nebraska and Hood River, Oregon Apply for HRSA 14 108 Funding Number: HRSA 14 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Social and Behavioral Datasets in Aging (R03) Apply for RFA AG 14 008 Funding Number: RFA AG 14 008 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Clinical Research in the Prevention, Diagnosis, and Treatment of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 023 Funding Number: RFA HL 14 023 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01) Apply for RFA AI 13 055 Funding Number: RFA AI 13 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY14 Region 5 Ohio(Athens, Crawford, DelawareFranklin, Hocking, Lucas, Madison, Mahoning, Marion, Medina, Pickaway, Portage, Richland, Stark, Summit, Trumbull, Union and Wayne counties )Announcement of Anticipated Availability of Funds for Family Apply for PA FPH 14 033 Funding Number: PA FPH 14 033 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,924,926 |
| FY14 Region 6 Louisiana(entire state)Announcement of Anticipated Availability of Funds for Family Planning Services Grants Apply for PA FPH 14 034 Funding Number: PA FPH 14 034 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,745,826 |
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 14 006 Funding Number: HRSA 14 006 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season Apply for RFA IP 14 001 Funding Number: RFA IP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Affordable Care Act Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 14 060 Funding Number: HRSA 14 060 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Primary Care Services Resources Coordination and Development Apply for HRSA 14 001 Funding Number: HRSA 14 001 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood and Vascular Systems Response to Sepsis (R01) Apply for RFA HL 14 028 Funding Number: RFA HL 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| STD/HIV Disease Intervention Services Training Centers (DISTC) Apply for CDC RFA PS14 1408 Funding Number: CDC RFA PS14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 059 Funding Number: HRSA 14 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Replication of Key Clinical Trials Initiative (U01) Apply for PAR 13 383 Funding Number: PAR 13 383 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Evidence Base and Capacity for Implementing HIV Prevention and Care and Treatment Programs in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1403 Funding Number: CDC RFA GH14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 1405 Funding Number: CDC RFA PS14 1405 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) Apply for RFA AA 14 001 Funding Number: RFA AA 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 14 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.